RxDoctor Payments Data

Martin Solorzano, MD

Internal Medicine · Tampa, FLNPI 1316942949

Payments from drug & device makers

$5,008in general payments, 2019–2025

Across 244 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$852
  • Boehringer Ingelheim$726
  • AstraZeneca$576
  • Amgen$347
  • Pfizer$307
  • Lilly USA, LLC$270
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,008 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$134,129
Medicare patients
216
Services billed
1,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$89,658
JardianceEmpagliflozin64$57,490
EliquisApixaban51$42,351
FarxigaDapagliflozin Propanediol37$30,020
TrulicityDulaglutide25$27,975
RybelsusSemaglutide18$24,833
JanuviaSitagliptin Phosphate12$7,011
Dexlansoprazole DrDexlansoprazole16$5,182
Atorvastatin Calcium503$4,872
Omeprazole167$3,251
Amlodipine Besylate454$2,961
Fluticasone Propionate206$2,919
Losartan Potassium358$2,902
SynthroidLevothyroxine Sodium34$2,489
Levothyroxine Sodium251$2,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$852$114,49180 claims
Boehringer IngelheimJardiance$726$57,49064 claims
PfizerEliquis$307$42,35151 claims
AstraZenecaFarxiga$576$30,02037 claims
Lilly USA, LLCTrulicity$270$27,97525 claims
MerckJanuvia$47$7,01112 claims
AbbVieSynthroid$229$2,48934 claims
Sanofi-aventis U.S. LLCLantus$92$1,23821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →